PMID- 36434131
OWN - NLM
STAT- MEDLINE
DCOM- 20221129
LR  - 20230112
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Nov 25
TI  - The clinical impact of donor against recipient HLA one way mismatch on the 
      occurrence of graft versus host disease in liver transplantation.
PG  - 20337
LID - 10.1038/s41598-022-24778-2 [doi]
LID - 20337
AB  - Graft versus host disease (GVHD) after liver transplantation (LT) is a rare, 
      fatal disease. This study aimed to evaluate the risk factors of GVHD after LT 
      including the human leukocyte antigen (HLA) donor-recipient relationship after 
      LT. LT recipients, who underwent HLA typing together with donors, were included 
      in the study. The donor against recipient (D --> R) one-way mismatch of HLA loci 
      was evaluated. HLA relationships, along with basic characteristics, were analyzed 
      as variable factors of GVHD, graft survival, and patient survival. A total of 994 
      living donor LT (LDLT) and 393 deceased donor LT (DDLT) patients were included. 
      Nine patients had suffered GVHD, four LDLT with D --> R one-way at three loci, one 
      LDLT without D --> R one-way at three loci, and four DDLT without D --> R one-way at 
      three loci. Four (57.1%) of seven LDLT patients, with D --> R one-way mismatch at 
      three loci, developed GVHD. D --> R one-way mismatch at three loci was related to 
      high GVHD incidence (HR 787, p < 0.001, multivariate). D --> R one-way mismatch at 
      three loci was related to graft failure and patient death (HR 9.90, p = 0.020 and 
      HR 12.8, p < 0.001, respectively, multivariate). Only one GVHD without D --> R 
      one-way mismatch at three loci, survived despite receiving multiple modalities 
      including tumor necrosis factor-alpha inhibitors. D --> R one-way mismatch at three 
      loci was significantly related to GVHD incidence after LT.
CI  - (c) 2022. The Author(s).
FAU - Kim, Sang Jin
AU  - Kim SJ
AD  - Department of Surgery, Korea University College of Medicine, Seoul, Republic of 
      Korea.
AD  - Division of Hepatobiliopancreas and Transplant Surgery, Korea University Ansan 
      Hospital, Ansan, Republic of Korea.
FAU - Park, Sunghae
AU  - Park S
AD  - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
FAU - Rhu, Jinsoo
AU  - Rhu J
AUID- ORCID: 0000-0001-9809-8525
AD  - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea. 
      jsrrules@gmail.com.
FAU - Kim, Jong Man
AU  - Kim JM
AD  - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
FAU - Choi, Gyu-Seong
AU  - Choi GS
AD  - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
FAU - Joh, Jae-Won
AU  - Joh JW
AD  - Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of 
      Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221125
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
EIN - Sci Rep. 2022 Dec 30;12(1):22598. PMID: 36585441
MH  - Humans
MH  - *Liver Transplantation/adverse effects
MH  - *Graft vs Host Disease
MH  - HLA Antigens/genetics
MH  - Living Donors
MH  - Histocompatibility Testing
MH  - Histocompatibility Antigens Class II
MH  - Rare Diseases/complications
PMC - PMC9700759
COIS- The authors declare no competing interests.
EDAT- 2022/11/27 06:00
MHDA- 2022/11/30 06:00
PMCR- 2022/11/25
CRDT- 2022/11/26 11:28
PHST- 2022/07/25 00:00 [received]
PHST- 2022/11/21 00:00 [accepted]
PHST- 2022/11/26 11:28 [entrez]
PHST- 2022/11/27 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/11/25 00:00 [pmc-release]
AID - 10.1038/s41598-022-24778-2 [pii]
AID - 24778 [pii]
AID - 10.1038/s41598-022-24778-2 [doi]
PST - epublish
SO  - Sci Rep. 2022 Nov 25;12(1):20337. doi: 10.1038/s41598-022-24778-2.